Ghost Tree Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Ghost Tree Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6,500	Closed	-$1.74M	–	77
2024 Q1	$1.74M	Sell	6,500 -8,500	-57%	-$2M	0.48%	57
2023 Q4	$3.47M	Sell	15,000 -42,500	-74%	-$7.44M	1.13%	29
2023 Q3	$8.4M	Buy	57,500 +2,500	+5%	+$471K	2.76%	7
2023 Q2	$12.7M	Buy	55,000 +25,000	+83%	+$6.77M	4.19%	8
2023 Q1	$7.27M	Buy	30,000 +10,000	+50%	+$2.72M	2.15%	18
2022 Q4	$5.8M	Sell	20,000 -5,000	-20%	-$489K	2.48%	17
2022 Q3	$1.63M	Buy	+25,000	New	+$1.74M	0.46%	40
2019 Q1	–	Sell	-900	Closed	-$101K	–	41
2018 Q4	$101K	Sell	900 -13,300	-94%	-$2.06M	0.04%	40
2018 Q3	$3.04M	Sell	14,200 -9,300	-40%	-$2.33M	0.65%	40
2018 Q2	$6.57M	Buy	+23,500	New	+$4.13M	1.93%	20

Other funds holding MDGL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ghost Tree Capital's MDGL Position: Q2 2024 in Review

Ghost Tree Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2024, closing a stake of 6,500 shares — an estimated $1.74M sold.

Ghost Tree Capital first reported a position in MDGL in Q2 2018 and held it in 10 quarters. The position peaked at $12.7M in Q2 2023. 257 funds tracked by Wall St. Rank hold MDGL as of Q2 2024.

Ghost Tree Capital reported no remaining Madrigal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Ghost Tree Capital sold 6,500 Madrigal Pharmaceuticals shares in Q2 2024, an estimated $1.74M.
Ghost Tree Capital first reported a position in Madrigal Pharmaceuticals in Q2 2018 and held it in 10 quarters.
Ghost Tree Capital's Madrigal Pharmaceuticals position peaked at $12.7M in Q2 2023.
257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2024.

Based on Ghost Tree Capital's 13F filing for Q2 2024, filed 14 Aug 2024.